Market LIVE
Published markets; coverage varies by country
Product profile · United States

VASOPRESSIN

 ·  Patent Litigation & Settlement History ↓

IngredientVASOPRESSIN
Application typeNDA
Application212593
Product001
Dosage formSOLUTION
RouteINTRAVENOUS
Strength20UNITS/ML (20UNITS/ML)
Approval date2020-08-03
Marketing statusPrescription
Status event—
ApplicantAM REGENT
Product source

Current GenericRadar decision

Year2020
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeAPPROVAL_YEAR_FALLBACK
Anchor date2020-08-03
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA—
Status event—

No verified direct-reference Final ANDA or unrestricted TrueDS/DS-equivalent/full-coverage exclusivity anchor is established for this exact product. Apply the approval-year DR fallback under the review policy. FDA letters for the available vasopressin ANDAs identify VASOSTRICT, including the exact 200 units/10 mL letter 212069, not separate NDA 212593.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-11 · CURRENT_SNAPSHOT_NO_RECORD · Historical coverage: NOT_COMPLETE

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
211538 / 001FINAL_APPROVAL · FINAL_APPROVED2021-12-15—EAGLE PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211857 / 001FINAL_APPROVAL · FINAL_APPROVED2022-07-18—AMPHASTAR PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212944 / 001FINAL_APPROVAL · FINAL_APPROVED2022-08-05—AMNEAL EU LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
214314 / 001FINAL_APPROVAL · FINAL_APPROVED2022-08-15—EUGIA PHARMA SPECIALITIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213206 / 001FINAL_APPROVAL · FINAL_APPROVED2023-05-26—FRESENIUS KABI USA LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
216963 / 001FINAL_APPROVAL · FINAL_APPROVED2024-02-09—GLAND PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213988 / 001FINAL_APPROVAL · FINAL_APPROVED2024-05-08—DR REDDYS LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212068 / 001FINAL_APPROVAL · FINAL_APPROVED2026-05-06—SANDOZ INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 8 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
211538 / 001EAGLE PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2021-12-15 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211857 / 001AMPHASTAR PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2022-07-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212944 / 001AMNEAL EU LTDFINAL_APPROVAL · FINAL_APPROVED2022-08-05 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
214314 / 001EUGIA PHARMA SPECIALITIES LTDFINAL_APPROVAL · FINAL_APPROVED2022-08-15 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213206 / 001FRESENIUS KABI USA LLCFINAL_APPROVAL · FINAL_APPROVED2023-05-26 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
216963 / 001GLAND PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2024-02-09 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213988 / 001DR REDDYS LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2024-05-08 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212068 / 001SANDOZ INCFINAL_APPROVAL · FINAL_APPROVED2026-05-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
REGULATORY_STATUS2020-08-03DECISION_BASISNo verified direct-reference Final ANDA or unrestricted TrueDS/DS-equivalent/full-coverage exclusivity anchor is established for this exact product. Apply the approval-year DR fallback under the review policy. FDA letters for the available vasopressin ANDAs identify VASOSTRICT, including the exact 200 units/10 mL letter 212069, not separate NDA 212593.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.